Nippon Kayaku Kabushiki Kaisha

Toyota Tsusho America, Inc.

Nippon Kayaku Co., Ltd

Toshio Tanabe

Reiko Machida

Yoshihiko Umegae

Yayoi Irie

Hisako Takagi

Takao Yokoyama

John Bernard Buse

Kan Saiga

Kyuichi Nemoto

Isamu Koyama

Takako Mae

Steven D Wittlin

Atsuko Isoda

Tadaki Yasumura

Shuhei Kato

Eric A Button

Kathleen Dungan

A biosensor for electrochemically measuring a sample may include a first member made of an insulating material, an electrode system including a working electrode and a counter electrode formed on the first member, a second member fixed over the first member, a sample flow channel provided between the first member and the second member, a hydrophilic section provided on at least a part of the internal surface of the sample flow channel and extending from a first end near the electrode system to a second end on the opposite side, and a flow stop area provided on a section adjacent to the second end on the first member or on the internal surface of the sample flow channel.

Biosensor

In quickly assaying a blood component interfered by glucose and/or its derivative on the bedside or in a clinic or in assaying the same by a patient in his/her own home, there has been required an assay method wherein the whole blood can be used as a sample as such without resorting to a centrifuge or the like. A method of assaying a blood component to be used for assaying a blood component interfered by glucose and/or its derivative, characterized by comprising bringing the whole blood into contact with a substance capable of converting glucose and/or its derivative into another substance not interfering the assay and, simultaneously or subsequently, separating blood cells; a device to be used in the assay method; and a kit containing this device.

Method of assaying 1,5 anhydroglucitol by using whole blood and measurement kit

By a method for measuring 1,5-anhydroglucitol, comprising the steps of: eliminating or converting glucose interfering with the measurement of 1,5-anhydroglucitol and/or a derivative thereof beforehand; and measuring 1,5-anhydroglucitol performed thereafter, wherein such glucose and/or a derivative thereof are/is eliminated or converted in whole blood as such without performing blood cell separation, an enzyme for measuring 1,5-anhydroglucitol is allowed to act on without performing blood cell separation, and 1,5-anhydroglucitol is electrochemically measured, it becomes possible to measure 1,5-anhydroglucitol using a small amount of whole blood without resort to a centrifuge or the like. Accordingly, this measurement method can be applied to rapid measurement of 1,5-anhydroglucitol at bedside or in a medical examination room or to home self-measurement thereof by a patient.

Method for electrochemically measuring 1,5-anhydroglucitol in whole blood

The invention is a method of measuring blood glucose excursions in general, and postprandial hyperglycemia in diabetic patients in particular, by the 1,5-anhydroglucitol assay (1,5-AG) or A1C/1,5-AG assay combination. 1,5-AG levels and percent changes of 1,5-AG levels in short period are indicative of differing postmeal glucose levels in moderately-controlled diabetic patients with similar A1C levels. Thereby 1,5-AG assay is useful to identify diabetic patients who may be at risk for cardiovascular complications which would not be identifiable by A1C levels alone. Furthermore, ratios of A1C divided by 1,5-AG in each patient are superior indicators to 1,5-AG levels.

Method of estimation of blood glucose excursions in diabetic patients using 1,5-anhydroglucitol (1,5-AG) assay

A method for detecting the onset of chronic rejection at an early stage after organ transplantation, characterized by assaying nitrogen trioxide (NO,), matrix metalloproteinase (MMP)-2 or the precursor thereof in body fluids drawn out of body.

Method for examining chronic rejection reactions following organ transplantation and method for determining urine components

Growing community of inventors

Takasaki, Japan

Toshio Tanabe